CN102869350A - 稳定的药物组合物 - Google Patents
稳定的药物组合物 Download PDFInfo
- Publication number
- CN102869350A CN102869350A CN2011800195930A CN201180019593A CN102869350A CN 102869350 A CN102869350 A CN 102869350A CN 2011800195930 A CN2011800195930 A CN 2011800195930A CN 201180019593 A CN201180019593 A CN 201180019593A CN 102869350 A CN102869350 A CN 102869350A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- lyrica
- weight
- stable pharmaceutical
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 54
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims abstract description 96
- 229920005862 polyol Polymers 0.000 claims abstract description 28
- 150000003077 polyols Chemical class 0.000 claims abstract description 28
- 150000002016 disaccharides Chemical class 0.000 claims abstract description 25
- 239000003381 stabilizer Substances 0.000 claims abstract description 24
- 206010015037 epilepsy Diseases 0.000 claims abstract description 7
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 5
- 229940009697 lyrica Drugs 0.000 claims description 94
- 239000000203 mixture Substances 0.000 claims description 69
- 238000002360 preparation method Methods 0.000 claims description 39
- -1 hydroxyl isomaltulose Chemical compound 0.000 claims description 36
- 239000002775 capsule Substances 0.000 claims description 29
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 12
- 208000002193 Pain Diseases 0.000 claims description 12
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 12
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 12
- 238000005984 hydrogenation reaction Methods 0.000 claims description 10
- 208000020925 Bipolar disease Diseases 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 229920001282 polysaccharide Polymers 0.000 claims description 7
- 239000005017 polysaccharide Substances 0.000 claims description 7
- 150000004804 polysaccharides Chemical class 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 208000019901 Anxiety disease Diseases 0.000 claims description 6
- 230000036506 anxiety Effects 0.000 claims description 6
- 229920001542 oligosaccharide Polymers 0.000 claims description 6
- 150000002482 oligosaccharides Chemical class 0.000 claims description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 208000006083 Hypokinesia Diseases 0.000 claims description 4
- 206010021639 Incontinence Diseases 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 4
- 206010028347 Muscle twitching Diseases 0.000 claims description 4
- 241001597008 Nomeidae Species 0.000 claims description 4
- 206010038419 Renal colic Diseases 0.000 claims description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 4
- 230000007850 degeneration Effects 0.000 claims description 4
- 230000003483 hypokinetic effect Effects 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 206010022437 insomnia Diseases 0.000 claims description 4
- 210000003205 muscle Anatomy 0.000 claims description 4
- 230000001537 neural effect Effects 0.000 claims description 4
- 208000004296 neuralgia Diseases 0.000 claims description 4
- 208000021722 neuropathic pain Diseases 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000000832 lactitol Substances 0.000 claims description 3
- 235000010448 lactitol Nutrition 0.000 claims description 3
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 3
- 229960003451 lactitol Drugs 0.000 claims description 3
- SQNRKWHRVIAKLP-RSZZQXBVSA-N (2r,3r,4r)-2,3,5-trihydroxy-4-[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxypentanal Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O SQNRKWHRVIAKLP-RSZZQXBVSA-N 0.000 claims description 2
- JCSJTDYCNQHPRJ-UHFFFAOYSA-N 20-hydroxyecdysone 2,3-acetonide Natural products OC1C(O)C(O)COC1OC1C(O)C(O)C(OC2C(C(O)C(O)OC2)O)OC1 JCSJTDYCNQHPRJ-UHFFFAOYSA-N 0.000 claims description 2
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 claims description 2
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 2
- RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims description 2
- LUEWUZLMQUOBSB-UHFFFAOYSA-N UNPD55895 Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(OC3C(OC(O)C(O)C3O)CO)C(O)C2O)CO)C(O)C1O LUEWUZLMQUOBSB-UHFFFAOYSA-N 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- JCSJTDYCNQHPRJ-FDVJSPBESA-N beta-D-Xylp-(1->4)-beta-D-Xylp-(1->4)-D-Xylp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)C(O)OC2)O)OC1 JCSJTDYCNQHPRJ-FDVJSPBESA-N 0.000 claims description 2
- FYGDTMLNYKFZSV-ZWSAEMDYSA-N cellotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-ZWSAEMDYSA-N 0.000 claims description 2
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 claims description 2
- UYQJCPNSAVWAFU-UHFFFAOYSA-N malto-tetraose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)O1 UYQJCPNSAVWAFU-UHFFFAOYSA-N 0.000 claims description 2
- LUEWUZLMQUOBSB-OUBHKODOSA-N maltotetraose Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O[C@@H]3[C@@H](O[C@@H](O)[C@H](O)[C@H]3O)CO)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-OUBHKODOSA-N 0.000 claims description 2
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 229920001221 xylan Polymers 0.000 claims description 2
- 150000004823 xylans Chemical class 0.000 claims description 2
- ABKNGTPZXRUSOI-UHFFFAOYSA-N xylotriose Natural products OCC(OC1OCC(OC2OCC(O)C(O)C2O)C(O)C1O)C(O)C(O)C=O ABKNGTPZXRUSOI-UHFFFAOYSA-N 0.000 claims description 2
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 claims description 2
- 239000007948 fast release tablet Substances 0.000 claims 1
- 239000006191 orally-disintegrating tablet Substances 0.000 claims 1
- 229920000151 polyglycol Polymers 0.000 claims 1
- 239000010695 polyglycol Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229960001233 pregabalin Drugs 0.000 abstract description 5
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 150000003951 lactams Chemical class 0.000 description 44
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical group NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 40
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 30
- 239000012535 impurity Substances 0.000 description 17
- 229960002870 gabapentin Drugs 0.000 description 15
- 239000003814 drug Substances 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 229920000881 Modified starch Polymers 0.000 description 7
- 239000002131 composite material Substances 0.000 description 7
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- SERLAGPUMNYUCK-YJOKQAJESA-N 6-O-alpha-D-glucopyranosyl-D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-YJOKQAJESA-N 0.000 description 6
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 239000000811 xylitol Substances 0.000 description 6
- 235000010447 xylitol Nutrition 0.000 description 6
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 6
- 229960002675 xylitol Drugs 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000008120 corn starch Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 229960001855 mannitol Drugs 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 150000005846 sugar alcohols Polymers 0.000 description 5
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229960005150 glycerol Drugs 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000001449 anionic compounds Chemical class 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229910001412 inorganic anion Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 150000002772 monosaccharides Chemical group 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035943 smell Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 229940080313 sodium starch Drugs 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- LUAHEUHBAZYUOI-KVXMBEGHSA-N (2s,3r,4r,5r)-4-[(2r,3r,4r,5s,6r)-5-[(2r,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexane-1,2,3,5,6-pentol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O[C@@H]([C@H](O)[C@@H](O)CO)[C@H](O)CO)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 LUAHEUHBAZYUOI-KVXMBEGHSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- TYCHBDHDMFEQMC-UHFFFAOYSA-N 3-(dimethylamino)-2-methylprop-2-enoic acid Chemical compound CN(C)C=C(C)C(O)=O TYCHBDHDMFEQMC-UHFFFAOYSA-N 0.000 description 1
- PWSUQCRPENFXDF-UHFFFAOYSA-N 4-cyclohexylpyrrolidin-2-one Chemical compound C1NC(=O)CC1C1CCCCC1 PWSUQCRPENFXDF-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 229920003083 Kollidon® VA64 Polymers 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- XJCCHWKNFMUJFE-CGQAXDJHSA-N Maltotriitol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O[C@@H]([C@H](O)[C@@H](O)CO)[C@H](O)CO)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 XJCCHWKNFMUJFE-CGQAXDJHSA-N 0.000 description 1
- NBGXQZRRLOGAJF-UHFFFAOYSA-N Maltulose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)(CO)OCC1O NBGXQZRRLOGAJF-UHFFFAOYSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 229930182474 N-glycoside Natural products 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000013590 bulk material Substances 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- VQHSOMBJVWLPSR-WELRSGGNSA-N cellobiotol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WELRSGGNSA-N 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 150000002341 glycosylamines Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- JCQLYHFGKNRPGE-HFZVAGMNSA-N maltulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-HFZVAGMNSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000007909 melt granulation Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- IQSHMXAZFHORGY-UHFFFAOYSA-N methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O IQSHMXAZFHORGY-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000008587 neuronal excitability Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 description 1
- 229960005318 vigabatrin Drugs 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 150000003953 γ-lactams Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及稳定的药物组合物,其包含普瑞巴林和作为稳定剂的二糖或高级多元醇和任选的常用药学可接受的载体。本发明稳定的药物组合物用于治疗许多疾病,例如癫痫、阿尔茨海默病或帕金森病。
Description
发明领域
本发明涉及γ-氨基丁酸("GABA")类似物的稳定的药物组合物及其制备方法。特别地,本发明涉及包含GABA类似物和作为稳定剂的二糖或高级多元醇(higher polyol)的稳定的药物组合物。
背景技术
γ-氨基丁酸("GABA")是哺乳动物中枢神经系统中的主要抑制性神经递质。GABA通过结合特异性跨膜受体(Cl--通道-偶联GABAA受体和G-蛋白-偶联GABAB受体)调节神经元兴奋性,导致静息膜电位稳定或超极化。衰减GABA能神经传递涉及人的几种中枢神经系统障碍的病理生理学,即焦虑、癫痫发作、运动障碍、惊恐、抑郁症、酒精中毒、疼痛和躁狂行为,由此本领域合成和描述了大量GABA类似物。在合成的GABA类似物中,加巴喷丁、普瑞巴林、氨己烯酸和巴氯芬已经在市场上销售并且用于治疗不同障碍。5-甲基-3-氨甲基-己酸(称作普瑞巴林)是GABA类似物,其通过结合中枢神经系统中神经元上的电压门控的钙通道的辅助α-2-δ亚单位降低中枢神经元兴奋性。美国专利5,563,175和6,197,819中公开的在美国以名称销售的普瑞巴林用于治疗外周神经性疼痛、癫痫和一般焦虑症。普瑞巴林还有效地治疗障碍中的慢性痛,例如纤维肌痛和脊髓损伤。美国专利6,117,906公开了普瑞巴林在治疗焦虑中的应用;美国专利6,001,876公开了普瑞巴林在治疗疼痛中的应用;美国专利6,127,418公开了普瑞巴林在治疗胃肠道损害中的应用。PCT公开号W098/58641公开了普瑞巴林作为抗炎药的应用。
GABA类似物的一个显著性问题在于形成毒性杂质,例如在合成和/或配制和/或贮存过程中相应的γ-内酰胺类。GABA类似物的氨基与其羧基官能团反应,形成内酰胺类。这种因GABA类似物分子内的氨基与羧基之间分子内缩合形成相应内酰胺导致的自动降解在配制GABA类似物的过程中呈现了严重的困难并且因安全原因而需要减少到最低限度。在通常的贮存条件下且还在有水的存在下的GABA类似物倾向于形成不期望的内酰胺副产物。可以用于配制GABA类似物制剂的多数赋形剂倾向于随时间的推移通过加速GABA类似物分子内氨基与羧基之间的脱水反应与它们反应,形成相应的内酰胺。此外,在制备药物制剂的过程中GABA类似物与制剂赋形剂之间的反应借助于使用水或有机溶剂进一步得到加速。这种GABA类似物随时间推移因形成内酰胺导致的降解归因于其化学结构并且因水的影响而发展,与GABA类似物是溶液状态还是固体无关。就加巴喷丁而言,分子内内酰胺4-环己基吡咯烷酮被视为比加巴喷丁更具有毒性。普瑞巴林(4-异丁基-吡咯烷-2-酮)的环内酰胺也是不期望的副产物。因此,在GABA类似物药物组合物研发和贮存期限过程中控制和监测内酰胺杂质是重要的参数。
此外,GABA分子中存在的伯氨基不仅能够形成内酰胺环,而且与其他还原羰基官能团反应。还已知使用赋形剂,例如乳糖,普瑞巴林通过进行美拉德反应形成共轭物。该反应的产物是简单的葡基胺,其为水净耗尽后乳糖与普瑞巴林胺的组合。经测定所配制的普瑞巴林中鉴定的约7种降解物是美拉德反应得到的普瑞巴林共轭物(参考文献)。此外,发现内酰胺形成与这些普瑞巴林共轭物一起出现。因此,期望提供不含形成共轭物的赋形剂的药物组合物,由此基本上不含这种共轭物且确保贮存条件下的稳定性。
本领域中描述了各种尝试以减少整批材料和最终单位剂型中GABA类似物形成相应内酰胺的趋势,并且提供其稳定的制剂。美国专利6,054,482涉及包含小于20ppm无机酸阴离子的加巴喷丁的制备方法。所述的药物组合物主要由以下成分组成:(i)游离氨基酸结晶无水形式的加巴喷丁的活性成分,这种结晶无水形式包含小于0.5%重量的其相应内酰胺和小于20ppm的无机酸阴离子;和(ii)一种或多种药学可接受的佐剂(adjuvant),在25℃和50%大气湿度下贮存1年时,它们不会促使超过0.2%重量的加巴喷丁转化成其相应的内酰胺形式,这些佐剂选自羟丙基甲基纤维素、聚乙烯吡咯烷酮、交聚维酮、伯洛沙姆407、伯洛沙姆188、羟基乙酸淀粉钠、交联聚维酮、玉米淀粉、环糊精、乳糖、滑石粉和二甲氨基-甲基丙烯酸和中性甲基丙烯酸酯共聚物。
欧洲专利1077692B1描述了α氨基酸作为稳定剂在药物制剂中的应用,这些药物制剂包含4-氨基-3-取代的-丁酸衍生物,例如加巴喷丁或普瑞巴林,由此防止因分子内自动缩合导致的内酰胺形成。欧洲专利1077691B1涉及4-氨基-3-取代的-丁酸衍生物制剂,其中通过使用保湿剂作为稳定剂阻断蒸发和少量残留水进入固体组合物防止因配制和贮存过程中内酰胺形成导致的降解。PCT出版物2008/003285公开了普瑞巴林的稳定的组合物,其包含一种或几种助剂,例如碱土金属磷酸盐或戊五醇和/或己糖醇或聚丙烯酸酯并且基本上不含糖类例如乳糖且无需氨基酸用于稳定。PCT出版物2005/051384涉及碳酸钙作为稳定剂在氨基酸例如普瑞巴林或加巴喷丁的固体药物组合物中的应用。美国专利6,488,964涉及普瑞巴林的包衣颗粒的制备方法,其内酰胺含量小于0.5%,其中将聚甲基丙烯酸酯、甲基丙烯酸氨乙酯共聚物和纤维素聚合物的单独或作为混合物在至少一种有机溶剂中的包衣溶液喷在所述颗粒上。美国专利申请2008/0058420A1涉及药物组合物,其包含加巴喷丁和能够将加巴喷丁转化成相应的内酰胺杂质的赋形剂混合物,其包含:(i)选自乳酸的钙盐的滑动剂;(ii)选自氢化蓖麻油和山嵛酸甘油酯的润滑剂;和任选的(iii)稀释剂,其选自单糖,如山梨醇、木糖醇、甘露醇、果糖、葡萄糖和赤藻糖醇;和多糖衍生物,如蔗糖、甘露醇、异麦芽酮糖醇(isomalt)、麦芽糖醇、半乳甘露聚糖、藻酸或其盐之一、果胶、鹿角菜胶和麦芽糖糊精。公开了基于使用三组赋形剂的加巴喷丁组合物,但尚未讨论具体组的赋形剂导致稳定或减少加巴喷丁转化成相应的内酰胺杂质。认为在25℃与60%相对湿度和/或30℃与65%相对湿度的贮存条件下维持3个月后,在这些组合物中相应的内酰胺杂质不超过加巴喷丁重量的0.2%。
欧洲专利申请1395242A涉及液体药物组合物,其包含GABA类似物,例如加巴喷丁或普瑞巴林和一种或多种包含2-6个碳原子的多元脂族醇,其选自:甘油、木糖醇、山梨醇、甘露醇和甘油与木糖醇的混合物,其中该组合物具有约5.5-约7.0的pH并且在2℃-10℃贮存18个月-2年后分别包含小于0.5%重量的加巴喷丁内酰胺或普瑞巴林内酰胺。一种或多种多元醇类占组合物重量/体积的约25%-约75%。欧洲专利申请1543831A涉及用于口服给药的水性药物组合物,其包含溶于或分散于包含适合的佐剂的水性液体的普瑞巴林,其特征在于将药物制剂的酸度调整至低于6.5-高于5.5稳定的pH-范围,并且通过以3:1-5:1的w/v比组合对羟基苯甲酸甲酯和对羟基苯甲酸乙酯对液体制剂防腐。PCT出版物2007/107835涉及包含GABA类似物和含有2-6个碳原子的多元醇的稳定口服液体制剂,其中包含2-6个碳原子的选自甘油、木糖醇、甘露醇及其混合物的多元醇含量等于或小于组合物重量/体积(w/v)的20%。认为该组合物在约2℃-10℃贮存18个月-2年后具有小于0.5%重量的相应内酰胺类似物。
鉴于上述描述,有必要提供基本上不含任何内酰胺杂质的GABA类似物的药物组合物。尽管本领域中已经公开了一些稳定的药物组合物,但是期望拥有在贮存期限内具有极佳贮存稳定性与极低内酰胺形成的GABA类似物组合物。对不仅稳定、而且在贮存过程中具有期望的体外溶出率和生物利用度的组合物也存在需求。此外,对鉴定当用于GABA类似物药物组合物时防止GABA类似物降解成相应的内酰胺形式或将其减少至最低限度的赋形剂也存在需求。
本发明令人意外地发现,可以将GABA类似物、即普瑞巴林配制成具有低水平-普瑞巴林内酰胺与除海藻糖之外的二糖或高级多元醇作为稳定剂的稳定药物组合物。本发明提供了稳定的普瑞巴林药物组合物,相对于普瑞巴林重量,其内酰胺含量小于约0.2%重量,优选小于约0.15%重量。本发明提供了普瑞巴林的稳定的药物组合物的制备方法,相对于普瑞巴林重量的其内酰胺含量按重量计小于约0.2%重量,优选小于约0.15%重量。
发明内容
本发明涉及普瑞巴林的稳定的药物组合物。本发明涉及防止普瑞巴林在药物组合物中的降解,其中通过使用除海藻糖之外的二糖或高级多元醇来进行。此外,本发明提供了普瑞巴林组合物,相对于普瑞巴林重量,其内酰胺含量小于约0.2%重量,优选小于约0.15%重量。本发明还提供了这种稳定的组合物的制备方法。
发明详述
本发明提供了稳定的药物组合物,其包含普瑞巴林和除海藻糖之外的二糖或高级多元醇,其基本上不含任何内酰胺杂质。
此外,普瑞巴林可以以盐、溶剂合物、多晶型物、前药、水合物或其衍生物的形式使用,但不限于此。
术语"二糖或高级多元醇"是指氢化二糖、寡糖或多糖或其任意的衍生物。可以用于本发明组合物的一种或多种二糖多元醇包括、但不限于异麦芽酮糖醇、氢化麦芽酮糖、拉克替醇、麦芽糖醇、异麦芽糖醇或其衍生物。可以用于本发明组合物的一种或多种高级寡糖或多糖多元醇包括、但不限于麦芽三糖醇(maltotriitol)、麦芽四糖醇(maltotetraitol)或其他通过淀粉水解、然后氢化得到的氢化寡糖类和多糖类,纤维二糖醇(cellobiitol)、纤维三糖醇(cellotriitol)、木二糖醇(xylobiitol)、木三糖醇(xylotriitol)、菊三糖醇(inulotriitol)或其他通过水解纤维素、木聚糖类或果聚糖类例如菊糖、然后氢化得到的氢化寡糖类和多糖类。在一个实施方案中,所用的二糖多元醇是异麦芽酮糖醇、拉克替醇、麦芽糖醇或其对映体或衍生物。在另一个实施方案中,所用的二糖多元醇是异麦芽酮糖醇。
与本发明关联,异麦芽酮糖醇应理解为指两种立体异构体6-O-α-D-吡喃葡糖基-D-山梨醇(1,6-GPS)和1-O-α-D-吡喃葡糖基-D-甘露醇(1,1-GPM)的几乎等摩尔混合物,也称作商品名异麦芽酮糖醇变体也包括在术语"异麦芽酮糖醇"含义内且包括包含1,6-GPS和1,1-GPM的混合物,其特征在于定量比例(quantity ratios)的1,6-GPM与1,6-GPS,其不同于定量比例的异麦芽酮糖醇。例如,这种混合物公开在美国专利5,578,339中,由此有关包含1,1-GPM和1,6-GPS的糖醇混合物的定量组合物及其生产方法包括在本专利申请的公开内容中。因此,异麦芽酮糖醇变体可以是,例如10wt%-50wt% 1,6-GPS、2wt%-20wt%1,1-GPS和30wt%-70wt%1,1-GPM的混合物或5wt%-10wt%1,6-GPS、30wt%-40wt%1,1-GPS和45wt%-60wt%1,1-GPM的混合物。
术语"内酰胺杂质"或"相应的内酰胺"是指因GABA类似物或其任意衍生物的γ-氨基和羧基的分子内缩合反应产生的不期望的降解产物。这种普瑞巴林的环化产物是其相应的内酰胺或内酰胺杂质。
术语"基本上不含任何内酰胺杂质"是指相对于普瑞巴林重量,本发明的普瑞巴林组合物包含不超过约0.2%重量、优选不超过约0.15%重量的内酰胺。
普瑞巴林以约10%-约99%重量组合物的量存在于本发明组合物中。根据本发明,普瑞巴林以约10%-约90%重量组合物的量存在于本发明的药物组合物中。基于组合物总重,具有至多50mg普瑞巴林的本发明稳定的药物组合物优选包含约10%-约60%重量的普瑞巴林、更优选约20%-约50%重量的普瑞巴林,特别是25%重量的普瑞巴林。基于组合物总重,具有超过50mg普瑞巴林的本发明稳定的药物组合物优选包含约40%-约99%重量的普瑞巴林、更优选约50%-约85重量的普瑞巴林,特别是约70%-约80%重量的普瑞巴林。
存在于本发明药物组合物中的二糖或高级多元醇稳定剂的量占该组合物约0.01%-约75%重量。在一个实施方案中,存在于本发明药物组合物中的二糖或高级多元醇的量占该组合物约0.01%-约65%重量。在另一个实施方案中,存在于本发明药物组合物中的二糖或高级多元醇的量占该组合物约0.01%-约50%重量。根据本发明,异麦芽酮糖醇以占组合物重量约0.01%-约75%的量存在。此外,本发明药物组合物中普瑞巴林与稳定剂之比可以在约1:9-约9:1的范围。在本发明的一个实施方案中,普瑞巴林与异麦芽酮糖醇之比可以在约1:9-约9:1的范围。
术语"组合物"或"制剂"在用于本发明的目的时可以互换使用并且指适合于对患者给药的药物组合物。本发明的稳定的药物组合物可以是固体或液体剂型的形式。
本发明包含除海藻糖之外的二糖或高级多元醇的稳定的普瑞巴林固体制剂在与市售制剂比较时是稳定的且基本上不含内酰胺杂质。在一个实施方案中,令人意外地,包含除海藻糖之外的二糖或高级多元醇的稳定的普瑞巴林固体组合物在与市售普瑞巴林制剂比较时是稳定的且基本上不含内酰胺杂质。不希望受到任何理论约束,认为本发明基本上不含任何内酰胺杂质的固体药物组合物的高度期望的稳定性是基于如下事实:用于本发明的具有低吸湿性和非还原(non-reducing)二糖或高级多元醇稳定剂几乎不可能吸收任何水份,并且针对GABA类似物或其制剂接触环境水份或制剂内固有的平衡水份作为保护剂起作用。按照这种方式,GABA类似物在这种制剂中的降解显著减少。任何水份-诱导的降解包括环化和甚至加热脱水,例如因挤压引起并且因水份促进或催化或因离子吸引导致的脱水,这种被水诱导的情况借助于在本发明的药物组合物中使用稳定剂例如除海藻糖之外的二糖或高级多元醇得到显著减少。
此外,不希望受到任何理论约束,稳定剂例如具有低吸湿性且加热稳定的异麦芽酮糖醇提供了湿度稳定作用,由此不会加速导致普瑞巴林分子内自动缩合的任何降解反应。异麦芽酮糖醇实际上在25℃和至多85%相对湿度下不吸收水份且是非还原的,不会促成制剂中由于美拉德反应产生的颜色。因此,令人意外地发现异麦芽酮糖醇作为稳定剂在包含普瑞巴林的固体组合物中起作用。由于使用了异麦芽酮糖醇,所以制剂中存在的降解产物基本上得以减少且特别地,内酰胺形成减少到最低限度。异麦芽酮糖醇或除海藻糖之外的任何二糖或高级多元醇的应用还掩蔽了GABA类似物的苦味且由此除稳定组合物外还提供了掩蔽味道的组合物。
适合于稳定包含普瑞巴林的组合物的异麦芽酮糖醇或除海藻糖之外的任何二糖或高级多元醇的应用是令人意外的,因为具有类似化学结构的其他化合物例如非还原单糖类(例如木糖醇、木糖醇、甘露醇)和海藻糖随时间的推移导致这些包含普瑞巴林的混合物的外观和/或味道不可接受的改变。
尽管已知的杂质在所需的水平以下,但是药物组合物的颜色和气味(smell)的改变是不可接受的。颗粒聚集可以导致组合物的崩解改变。这些问题通过使用异麦芽酮糖醇或除海藻糖之外的任何二糖或高级多元醇也得到解决。
对本发明的液体组合物而言,令人意外地发现,二糖或高级多元醇类可以用作稳定剂,由此可以提供基本上不含任何内酰胺杂质的制剂,即相对于普瑞巴林重量包含不超过约0.2%重量、优选不超过约0.15%重量的内酰胺杂质。二糖或高级多元醇类在本发明的液体组合物中具有稳定和防腐效果。
本发明的稳定的药物组合物还可以包含至少一种药学可接受的赋形剂。所谓"药学可接受的赋形剂"是指无生物学的、或者以其它方式没有不期望的材料,即可以将该材料与药物和稳定剂一起在制剂中给予个体,不会导致任何不期望的生物效应或与它所包含在其中的制剂中的任何成分以有害方式发生相互作用。仅使用不含反应性醛基或酮基官能团的药学可接受的赋形剂,因为这些官能团与活性成分反应。
可以存在于本发明稳定的药物组合物中的药学可接受的赋形剂包括、但不限于稀释剂、粘合剂、崩解剂、润滑剂、着色剂、矫味剂、pH调节剂、粘性剂、人造和天然甜味剂等。可以任选掺入本发明组合物中的稀释剂包括、但不限于滑石粉、蔗糖、微晶纤维素、磷酸氢钙、淀粉、玉米淀粉、预胶化淀粉、部分预胶化淀粉等及其组合。可以用于本发明组合物中的粘合剂包括、但不限于微晶纤维素、聚乙二醇、聚乙烯吡咯烷酮、玉米淀粉、预胶化淀粉、部分预胶化淀粉、羟丙基甲基纤维素、羟丙基纤维素等或其组合。可以用于本发明组合物中的崩解剂包括、但不限于羟基乙酸淀粉钠、羧甲基纤维素钠、交联羧甲基纤维素钠、交聚维酮、聚乙烯吡咯烷酮、甲基纤维素、淀粉、预胶化淀粉、部分预胶化淀粉等或其组合。可以用于本发明组合物中的润滑剂包括、但不限于硬脂酸镁、硬脂酸钙、硬脂酸锌、硬脂酰醇富马酸钠等或其组合。
本发明稳定的普瑞巴林固体药物组合物以胶囊、片剂、颗粒、丸剂、粉末、锭剂、多颗粒等形式存在,但不限于此。本发明的药物组合物以分散片、干粉或重构(reconstitution)用颗粒的形式存在。在一个实施方案中,本发明的胶囊可以是速释或调释(modified release)类型,但不限于此。在另一个实施方案中,本发明的片剂可以是速释或调释类型或口腔崩解类型,但不限于此。
在另一个实施方案中,本发明的药物组合物可以是普瑞巴林的稳定的液体制剂形式。液体形式的配制剂包括溶液、糖浆剂、悬浮液和乳剂,例如水溶性或一些二醇溶液。为了胃肠外注射,可以将液体配制剂配制成在聚乙二醇水溶液中的溶液。
本发明还提供了包含普瑞巴林的稳定的药物组合物的制备方法。这种方法包括合并普瑞巴林与作为稳定剂的二糖或高级多元醇,如果必要,合并药学可接受的赋形剂。在一个实施方案中,二糖或高级多元醇稳定剂是异麦芽酮糖醇。此外,本发明涉及包含普瑞巴林的固体或液体形式的稳定的药物组合物的制备方法。在一个实施方案中,可以通过掺合活性成分和稳定剂与其他药学可接受的赋形剂、然后包囊在硬胶囊中制备本发明的稳定的固体组合物。在另一个实施方案中,可以制备普瑞巴林颗粒,例如用于填充入胶囊或通过本领域技术人员公知的任意制粒方法压制成片剂形式,包括但不限于干法制粒、湿法制粒、熔化制粒等,不会导致相应的普瑞巴林内酰胺形式形成,使得所提供的制剂基本上不含任何内酰胺杂质并且是稳定的。在另一个实施方案中,可以制备稳定剂或其他药学可接受的赋形剂的颗粒、丸剂等,并且用于配制本发明的稳定的药物组合物。可以任选给普瑞巴林的粉末、颗粒或片剂等表面包衣。表面包衣层可以是美化或功能性包衣层。可以通过众所周知的方法、使用流化床或旋转锅进行表面包衣。成膜材料例如、但不限于纤维素衍生物例如羟丙基纤维素(HPC)、羟丙基甲基纤维素(HPMC)等、聚乙烯吡咯烷酮、Kollidon-VA64、Eudragits等可以用于表面包衣。
在另一个实施方案中提供了本发明稳定的普瑞巴林药物组合物在制备用于治疗癫痫、昏晕发作、运动减少、颅创伤、神经变性障碍例如阿尔茨海默病、亨廷顿舞蹈症或帕金森病和肌萎缩侧索硬化、抑郁症、躁狂和双相性精神障碍、焦虑、惊恐性炎症、肾绞痛、失眠症、胃肠道损害、失禁、包括神经性疼痛、筋痛、骨痛和偏头痛的疼痛的药物中的应用。此外,本发明提供了癫痫、昏晕发作、运动减少、颅创伤、神经变性障碍例如阿尔茨海默病、亨廷顿舞蹈症或帕金森病和肌萎缩侧索硬化、抑郁症、躁狂和双相性精神障碍、焦虑、惊恐性炎症、肾绞痛、失眠症、胃肠道损害、失禁、包括神经性疼痛、筋痛、骨痛和偏头痛的疼痛的治疗方法,包括对有此需要的受试者给予本发明的稳定的药物组合物。
尽管在其具体的实施方案方面描述了本发明,但是一些变型和等效方案对本领域技术人员而言显而易见,且预以包括在本发明范围内。本发明进一步通过下列实施例示例,这些实施例用于示例目的,而不应被视为以任何方式限制本发明的范围。
实施例
实施例1/A
使用不同赋形剂的普瑞巴林稳定性对比评价
进行预制剂研究以评价不同物理方式混合的赋形剂对普瑞巴林稳定性的影响。通过HPLC测定预制剂(preformulation)混合物中的内酰胺含量百分比。
实施例1/B
使用非还原糖类的普瑞巴林的稳定性对比评价
进行预制剂研究以评价不同的以物理方式混合的非还原糖类对普瑞巴林稳定性的影响。
实施例2
具有25%药物含量的普瑞巴林胶囊制剂(1473-050-25)
成分 | mg/胶囊 |
普瑞巴林 | 25 |
异麦芽酮糖醇 | 35 |
部分预胶化淀粉,USP | 35 |
滑石粉,USP | 5 |
总计 | 100 |
将普瑞巴林和所有非滑石粉的赋形剂过筛并且掺合。向该掺合物中加入过筛的滑石粉并且进一步掺合。使用手动胶囊填充机将这种药物-赋形剂掺合物填充入胶囊。
体外溶出研究
测定
配方 | 最初 | 1M 40℃/75%RH |
LYRICA 25mg | 102.9 | 99.2 |
当前实施例的普瑞巴林胶囊 | 101.1 | 104.7 |
稳定性研究
因此,数据显示在本发明的普瑞巴林组合物中使用异麦芽酮糖醇有效地使其稳定。在40℃/75%相对湿度下PVC/Alu泡罩包装中的1个月稳定性数据显示内酰胺水平相对于GABA类似物重量显著低于0.05%重量。
实施例3
具有25%药物含量的普瑞巴林胶囊制剂(1573-093-25)
成分 | mg/胶囊 |
普瑞巴林 | 25 |
异麦芽酮糖醇 | 51 |
玉米淀粉,USP | 5 |
滑石粉,USP | 19 |
总计 | 100 |
体外溶出研究
测定
制剂 | 最初 | 1M 40℃/75%RH |
LYRICA 25mg | 102.9 | 99.2 |
本发明的普瑞巴林胶囊 | 102.6 | 103.7 |
稳定性研究
对本实施例中讨论的普瑞巴林胶囊和25mg市售胶囊的相关物质进行对比评价,将结果制成下表。
因此,数据显示在本发明的普瑞巴林组合物中使用异麦芽酮糖醇有效地使其稳定。在40℃/75%相对湿度下PVC/Alu泡罩包装中的1个月稳定性数据显示内酰胺水平相对于GABA类似物重量显著低于0.05%重量。
实施例4
具有25%药物含量的普瑞巴林胶囊制剂(1537-035-25)
成分 | mg/胶囊 |
普瑞巴林 | 25 |
异麦芽酮糖醇 | 45 |
玉米淀粉 | 11 |
滑石粉 | 19 |
总计 | 100 |
按照实施例2中所述的方法制备胶囊。
实施例5
具有75%药物含量的普瑞巴林胶囊制剂(1537-047-300)
成分 | mg/胶囊 |
普瑞巴林 | 300 |
异麦芽酮糖醇 | 68 |
滑石粉,USP | 32 |
总计 | 400 |
按照实施例2中所述的方法制备胶囊。
Claims (17)
1.稳定的药物组合物,包含普瑞巴林和作为稳定剂的除海藻糖之外的二糖或高级多元醇和任选的常用药学可接受的载体。
2.权利要求1的稳定的药物组合物,包含麦芽三糖醇、麦芽四糖醇或其他通过水解淀粉、然后氢化得到的氢化寡糖类和多糖类,纤维二糖醇、纤维三糖醇、木二糖醇、木三糖醇、菊三糖醇或其他通过水解纤维素、木聚糖类或果聚糖类、优选菊糖、然后氢化得到的氢化寡糖类和多糖类作为稳定剂。
3.权利要求1或2的稳定的药物组合物,包含异麦芽酮糖醇、拉克替醇、麦芽糖醇或其对映体或衍生物作为稳定剂。
4.权利要求1-3任一项的稳定的药物组合物,包含占该组合物总重10%-约60%重量的至多50mg的普瑞巴林/剂量单元。
5.权利要求4的稳定的药物组合物,包含占该组合物总重20%-50%重量、优选25%重量的普瑞巴林。
6.权利要求1-3任一项的稳定的药物组合物,包含占该组合物总重40-99%重量的超过50mg的普瑞巴林/剂量单元。
7.权利要求6的稳定的药物组合物,包含占该组合物总重50%-85%、优选70-80%的普瑞巴林。
8.权利要求1-7任一项的稳定的药物组合物,包含占该组合物总重0.01%-75%重量的二糖或高级多元醇。
9.权利要求8的稳定的药物组合物,包含占该组合物总重0.01%-65%重量、优选0.01%-50%重量的二糖或高级多元醇。
10.权利要求1-8任一项的稳定的药物组合物,包含占该组合物总重0.01%-75%重量的异麦芽酮糖醇作为稳定剂。
11.权利要求1-10任一项的稳定的药物组合物,包含1:9-9:1之比的GABA-类似物和稳定剂。
12.权利要求11任一项的稳定的药物组合物,包含1:9-9:1之比的普瑞巴林与异麦芽酮糖醇。
13.权利要求1-12任一项的稳定的药物组合物,其适合于口服或胃肠外给药。
14.权利要求13的稳定的药物组合物,其为分散片、包衣片、干粉、重构用颗粒、活性成分速释胶囊或活性成分调释胶囊、活性成分速释片或活性成分调释片或口服崩解片、溶液、糖浆剂、悬浮液和乳剂形式或水溶液或聚乙二醇溶液形式的胃肠外注射剂。
15.权利要求1-14任一项的稳定的药物组合物的制备方法,该方法包括混合普瑞巴林和作为稳定剂的除海藻糖之外的二糖或高级多元醇和任选的常用药学可接受的赋形剂,并且将混合物制成为直接医疗应用的备用形式。
16.权利要求1-14任一项的稳定的药物组合物在治疗或预防癫痫、昏晕发作、运动减少、颅创伤、神经变性障碍例如阿尔茨海默病、亨廷顿舞蹈症或帕金森病和肌萎缩侧索硬化、抑郁症、躁狂和双相性精神障碍、焦虑、惊恐性炎症、肾绞痛、失眠症、胃肠道损害、失禁、包括神经性疼痛、筋痛、骨痛或偏头痛的疼痛中的应用。
17.医学治疗或预防癫痫、昏晕发作、运动减少、颅创伤、神经变性障碍例如阿尔茨海默病、亨廷顿舞蹈症或帕金森病和肌萎缩侧索硬化、抑郁症、躁狂和双相性精神障碍、焦虑、惊恐性炎症、肾绞痛、失眠症、胃肠道损害、失禁、包括神经性疼痛、筋痛、骨痛或偏头痛的疼痛的方法,该方法包括对有这种治疗需要的患者给予有效量的权利要求1-14任一项的组合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU1000120A HU230031B1 (hu) | 2010-03-01 | 2010-03-01 | Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény |
HUP1000120 | 2010-03-01 | ||
PCT/HU2011/000019 WO2011107812A2 (en) | 2010-03-01 | 2011-03-01 | Stabilized pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102869350A true CN102869350A (zh) | 2013-01-09 |
Family
ID=89989589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011800195930A Pending CN102869350A (zh) | 2010-03-01 | 2011-03-01 | 稳定的药物组合物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US8968780B2 (zh) |
EP (1) | EP2542229A2 (zh) |
CN (1) | CN102869350A (zh) |
BR (1) | BR112012022255A2 (zh) |
EA (1) | EA021719B1 (zh) |
HU (1) | HU230031B1 (zh) |
MA (1) | MA34090B1 (zh) |
UA (1) | UA106907C2 (zh) |
WO (1) | WO2011107812A2 (zh) |
ZA (1) | ZA201207375B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103494796A (zh) * | 2013-09-30 | 2014-01-08 | 浙江华义医药有限公司 | 普瑞巴林稳定的药物组合物及其制备方法 |
CN104694355A (zh) * | 2015-03-20 | 2015-06-10 | 吉林大学 | 葛根护肝保健酒及其制备方法 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150374705A1 (en) | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
JP6919119B2 (ja) * | 2017-01-23 | 2021-08-18 | 日新製薬株式会社 | 3位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。 |
WO2019009927A1 (en) * | 2017-07-06 | 2019-01-10 | Adorus Pharmaceuticals Llc | MIXTURE COMPOSITIONS FOR ORAL ADMINISTRATION AS POWDER AND / OR SUSPENSION WITH RAPID DISSOLUTION |
JP6504638B1 (ja) * | 2018-05-31 | 2019-04-24 | 武田テバファーマ株式会社 | 錠剤及びその製造方法 |
CN110613689A (zh) * | 2018-06-19 | 2019-12-27 | 北京万全德众医药生物技术有限公司 | 一种含有两亲性聚合物-普瑞巴林复合物的口崩片 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002078747A2 (en) * | 2001-03-30 | 2002-10-10 | Warner-Lambert Company Llc | Pregabalin lactose conjugates |
WO2006008295A1 (en) * | 2004-07-20 | 2006-01-26 | Zambon Group S.P.A. | A pharmaceutical composition comprising gabapentin |
CN1827590A (zh) * | 2006-04-14 | 2006-09-06 | 北京润德康医药技术有限公司 | 一种普瑞巴林新晶型、制备方法及其药用组合物 |
WO2007107835A2 (en) * | 2006-03-17 | 2007-09-27 | Aurobindo Pharma Limited | Stable liquid formulations of antiepileptic agents |
WO2009066325A1 (en) * | 2007-11-23 | 2009-05-28 | Lupin Limited | Controlled release pharmaceutical compositions of pregabalin |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3928183A1 (de) | 1989-08-25 | 1991-02-28 | Goedecke Ag | Lactamfreie cyclische aminosaeuren |
US6197819B1 (en) | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
DE9321600U1 (de) | 1993-05-06 | 2000-04-06 | Suedzucker Ag | Süssungsmittel |
IL126999A (en) | 1996-07-24 | 2002-03-10 | Warner Lambert Co | Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain |
HRP980342A2 (en) | 1997-06-25 | 1999-02-28 | Warner Lambert Co | Anti-inflammatory method |
US6127418A (en) | 1997-08-20 | 2000-10-03 | Warner-Lambert Company | GABA analogs to prevent and treat gastrointestinal damage |
CA2327285C (en) | 1998-05-15 | 2005-06-14 | Warner-Lambert Company | Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same |
CU23051A3 (es) | 1998-05-15 | 2005-06-24 | Warner Lambert Co | Composiciones solidas que contienen derivados de acido gamma-aminobutirico y procesos para prepararlas. |
FR2781793B1 (fr) | 1998-08-03 | 2001-07-20 | Prographarm Lab | Procede de fabrication de granules de gabapentine enrobes |
PT1395242E (pt) | 2001-05-25 | 2006-11-30 | Warner Lambert Co | Composição farmacêutica líquida |
WO2003080588A1 (en) | 2002-03-20 | 2003-10-02 | Xenoport | Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof |
WO2005051384A1 (en) | 2003-11-25 | 2005-06-09 | Pfizer Limited | Stabilised pharmaceutical compositions |
EP1543831A1 (en) | 2003-12-18 | 2005-06-22 | Pfizer GmbH Arzneimittelwerk Gödecke | Pregabalin composition |
NL2000281C2 (nl) * | 2005-11-02 | 2007-08-07 | Pfizer Prod Inc | Vaste farmaceutische samenstellingen die pregabaline bevatten. |
DE102006030642A1 (de) | 2006-07-03 | 2008-01-10 | Conti Temic Microelectronic Gmbh | Identifikationssystem |
-
2010
- 2010-03-01 HU HU1000120A patent/HU230031B1/hu not_active IP Right Cessation
-
2011
- 2011-03-01 UA UAA201211360A patent/UA106907C2/uk unknown
- 2011-03-01 US US13/582,162 patent/US8968780B2/en not_active Expired - Fee Related
- 2011-03-01 EP EP11711993A patent/EP2542229A2/en not_active Withdrawn
- 2011-03-01 MA MA35251A patent/MA34090B1/fr unknown
- 2011-03-01 EA EA201290856A patent/EA021719B1/ru not_active IP Right Cessation
- 2011-03-01 CN CN2011800195930A patent/CN102869350A/zh active Pending
- 2011-03-01 WO PCT/HU2011/000019 patent/WO2011107812A2/en active Application Filing
- 2011-03-01 BR BR112012022255A patent/BR112012022255A2/pt not_active IP Right Cessation
-
2012
- 2012-10-02 ZA ZA2012/07375A patent/ZA201207375B/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002078747A2 (en) * | 2001-03-30 | 2002-10-10 | Warner-Lambert Company Llc | Pregabalin lactose conjugates |
WO2006008295A1 (en) * | 2004-07-20 | 2006-01-26 | Zambon Group S.P.A. | A pharmaceutical composition comprising gabapentin |
WO2007107835A2 (en) * | 2006-03-17 | 2007-09-27 | Aurobindo Pharma Limited | Stable liquid formulations of antiepileptic agents |
CN1827590A (zh) * | 2006-04-14 | 2006-09-06 | 北京润德康医药技术有限公司 | 一种普瑞巴林新晶型、制备方法及其药用组合物 |
WO2009066325A1 (en) * | 2007-11-23 | 2009-05-28 | Lupin Limited | Controlled release pharmaceutical compositions of pregabalin |
Non-Patent Citations (1)
Title |
---|
RAYMOND C ROWE ET AL.: "《Handbook of Pharmaceutical Excipients》", 31 December 2009, PHARMACEUTICAL PRESS, article "Isomalt", pages: 342-346 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103494796A (zh) * | 2013-09-30 | 2014-01-08 | 浙江华义医药有限公司 | 普瑞巴林稳定的药物组合物及其制备方法 |
CN103494796B (zh) * | 2013-09-30 | 2016-01-20 | 浙江华义医药有限公司 | 普瑞巴林稳定的药物组合物及其制备方法 |
CN104694355A (zh) * | 2015-03-20 | 2015-06-10 | 吉林大学 | 葛根护肝保健酒及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2011107812A3 (en) | 2011-11-10 |
WO2011107812A2 (en) | 2011-09-09 |
EA201290856A1 (ru) | 2013-02-28 |
EP2542229A2 (en) | 2013-01-09 |
HU1000120D0 (en) | 2010-04-28 |
BR112012022255A2 (pt) | 2016-10-25 |
US8968780B2 (en) | 2015-03-03 |
HU230031B1 (hu) | 2015-05-28 |
MA34090B1 (fr) | 2013-03-05 |
ZA201207375B (en) | 2014-03-26 |
UA106907C2 (uk) | 2014-10-27 |
HUP1000120A2 (en) | 2011-09-28 |
US20130064893A1 (en) | 2013-03-14 |
EA021719B1 (ru) | 2015-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102869350A (zh) | 稳定的药物组合物 | |
JP6173521B2 (ja) | ナルブフィンを含有する製剤及びそれらの使用 | |
JP4707073B2 (ja) | アトルバスタチン経口投与用粒子状医薬組成物 | |
EP2961383B1 (en) | Suspension for oral administration comprising amorphous tolvaptan | |
US10058536B2 (en) | Pharmaceutical composition containing mirabegron | |
CN103919715A (zh) | 含有甘磷酸胆碱或其盐的控释药物组合物及其制备方法 | |
JP5174909B2 (ja) | 活性成分のコーティング膜が保護される口腔内崩壊剤形を製造するための組成物 | |
US20160296463A1 (en) | Rapidly disintegrating formulations and methods thereof | |
US20150141520A1 (en) | Stabilized pharmaceutical compositions of fingolimod and process for preparation thereof | |
WO2013091704A1 (en) | Pharmaceutical composition comprising fingolimod | |
JP2011046666A (ja) | 医薬組成物 | |
US20070059354A1 (en) | Sustained release dosage forms of oxcarbazepine | |
US20240009133A1 (en) | Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs | |
WO2013190151A1 (en) | Pharmaceutical composition comprising fingolimod | |
JP5365949B2 (ja) | 低用量ラモセトロン含有口腔内崩壊錠 | |
EP3157510B1 (en) | Antimicrobial compositions with effervescent agents | |
JP7480983B2 (ja) | レベチラセタム含有製剤 | |
US20160022661A1 (en) | Dosage Form Comprising Crizotinib | |
WO2022155507A1 (en) | Transmucosal dosage forms of brexanolone | |
EP2996681B1 (en) | Pharmaceutical composition comprising fingolimod | |
JP2023008994A (ja) | アピキサバンの溶出性の改善方法 | |
WO2022229982A1 (en) | Oral formulations of edaravone and method of manufacturing thereof | |
WO2013022410A2 (en) | Production method for effervescent formulations comprising dexketoprofen | |
CN115803020A (zh) | 含有苯磺酸米洛巴林的口腔崩解片剂 | |
WO2013165327A1 (en) | Pharmaceutical formulations comprising thiocolchicoside |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1179880 Country of ref document: HK |
|
AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20170315 |
|
C20 | Patent right or utility model deemed to be abandoned or is abandoned | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1179880 Country of ref document: HK |